Early versus late follicular phase ovarian stimulation: a randomized controlled trial
Reproductive BioMedicine Online · 2024
DOI: 10.1016/j.rbmo.2024.103889 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Reproductive BioMedicine Online, 2024. Verfasst von Sylvie De Rijdt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Brussels IVF, Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Jette, Belgium. Hauptthemen laut MEDLINE: Follicular Phase, Gonadotropin-Releasing Hormone, Ovulation Induction. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Gedeon Richter Plc.
Abstract (Originalsprache)
RESEARCH QUESTION: Is late follicular phase stimulation as efficient as early follicular phase stimulation in a gonadotrophin-releasing hormone (GnRH) antagonist protocol in oocyte donors in terms of the number of oocytes. DESIGN: In this open label, phase 3, non-inferiority, randomized controlled trial using a two-arm design with a 1:1 allocation ratio, 84 oocyte donors were allocated to the early follicular start group (control group, n = 41) or the late follicular start group (study group, n = 43). In the control group, women followed a fixed GnRH antagonist protocol with recombinant FSH (r-FSH) 225 IU. In the study group, r-FSH 225 IU was initiated in the late follicular phase. The primary outcome was the number of oocytes. The secondary outcomes were the number of mature oocytes, consumption of gonadotrophins and GnRH antagonist, and cost of medication. RESULTS: The number of oocytes did not differ between the control group and the study group (intent-to-treat analysis 15.5 ± 11.0 versus 14.0 ± 10.7, P = 0.52; per-protocol analysis 18.2 ± 9.7 versus 18.8 ± 7.8, P = 0.62). In addition, the number of mature oocytes did not differ between the groups (14.1 ± 8.1 versus 12.7 ± 8.5, P = 0.48). The duration of stimulation was shorter in the control group (10.0 ± 1.4 versus 10.9 ± 1.5 days, P = 0.01). The total amount of r-FSH used was lower in the control group (2240.7 ± 313.9 IU versus 2453.9 ± 330.1 IU, P = 0.008). A GnRH antagonist was used for approximately 6 days in the control group, while a GnRH antagonist was only prescribed for one woman in the study group (6.0 ± 1.4 days versus 0.13±0.7 days, P < 0.001). There was a significant difference in the cost of medication per cycle between the groups (1147.9 ± 182.8€ in control group versus 979.9 ± 129.0€ in study group, P < 0.001). CONCLUSIONS: Late follicular phase stimulation is as efficient as early follicular phase stimulation in terms of the number of oocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brussels IVF, Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Jette, Belgium.
- Brussels IVF, Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Jette, Belgium. Electronic address: Christophe.Blockeel@uzbrussel.be.
Förderung
- Gedeon Richter Plc
Zitieren
APA
De Rijdt, S., Illingworth, K., De Munck, N., Tournaye, H., Mackens, S., De Vos, M., & Blockeel, C. (2024). Early versus late follicular phase ovarian stimulation: a randomized controlled trial. Reproductive BioMedicine Online. https://doi.org/10.1016/j.rbmo.2024.103889
Vancouver
De Rijdt S, Illingworth K, De Munck N, Tournaye H, Mackens S, De Vos M, et al. Early versus late follicular phase ovarian stimulation: a randomized controlled trial. Reproductive BioMedicine Online. 2024. doi:10.1016/j.rbmo.2024.103889
BibTeX
@article{DeRijdt2024,
author = {De Rijdt, Sylvie and Illingworth, Kim and De Munck, Neelke and Tournaye, Herman and Mackens, Shari and De Vos, Michel and Blockeel, Christophe},
title = {Early versus late follicular phase ovarian stimulation: a randomized controlled trial},
journal = {Reproductive BioMedicine Online},
year = {2024},
doi = {10.1016/j.rbmo.2024.103889}
}
EUVIMED